Editas Medicine, Inc. (EDIT)
Nasdaq: EDIT · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2015
Who owns Editas Medicine, Inc.
As filed with the SECHolders of 5% or more
5
TCG Crossover GP III, LLC holds 9.9% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13G filed Jun 3, 2026 says.
Directors and officers
10
report now, of 34 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
TCG Crossover GP III, LLC
SCHEDULE 13G · filed Jun 3, 2026 · Common Stock, $0.0001 par value per share
Commodore Capital LP
SCHEDULE 13G · filed Jun 2, 2026 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock · 4.97% in Jul 29, 2026
ADAR1 Capital Management, LLC
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share
RA Capital Management, L.P.
SCHEDULE 13G · filed Jun 3, 2026 · Common Stock, $0.0001 par value per share
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
Deep Track Capital, LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
What EDIT reports owning in othersstakes of 5% or more, and other ties
Editas Medicine, Inc. reports no stake in another company in the record.
Insider tradesForm 4
14sales
0purchases
14sales on a scheduled plan
3people selling
$100,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 54 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| O'Neill Gilmore Neil | CEO | 4 | $100,000 | 4 | 0 | $0 |
| Parison Amy | SVP, Chief Financial Officer | 5 | $0 | 5 | 0 | $0 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 5 | $0 | 5 | 0 | $0 |